Oxford Immunotec Schedules Third Quarter 2017 Earnings Release and Conference Call for October 31, 2017

OXFORD, United Kingdom and MARLBOROUGH, Mass., Oct. 17, 2017 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today announced that it plans to release third quarter 2017 financial results … [Read more...]

Canada House is Pleased to Announce Its Joint Venture With Nutritional High, an Expert in Cannabis Oil Extracts and Edibles

TORONTO, Oct. 17, 2017 (GLOBE NEWSWIRE) -- Canada House Wellness Group Inc.’s ("Canada House") (CSE:CHV) wholly owned subsidiary Abba Medix Corp. (“Abba”) and Nutritional High International Inc. ("Nutritional High") (CSE:EAT) (OTCQB:SPLIF) (FRANKFURT:2NU) have entered into a letter of intent ("LOI") to create a joint venture (“Joint Venture”) to manufacture cannabis oil … [Read more...]

OncBioMune Preparing to Initiate Trials of Novel Therapeutic Ovarian Cancer Vaccine

BATON ROUGE, La., Oct. 17, 2017 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a revenue-stage biopharmaceutical company engaged in the development of a proprietary cancer vaccine technology, targeted cancer therapies and commercialization of a portfolio of products internationally, is pleased to inform shareholders that the … [Read more...]

Significant advance in breast cancer care – Cohera Medical, Inc. ® Drain-Free Mastectomy trial reaches full enrollment

RALEIGH, N.C., Oct. 17, 2017 (GLOBE NEWSWIRE) -- Painful post-surgical drains may become unnecessary for breast cancer patients who undergo a mastectomy procedure (removal of the breast).  A level I clinical study seeks to provide evidence that the skin flap can be adhered to the chest wall with TissuGlu Surgical Adhesive® after removal of the breast tissue, assisting the … [Read more...]

Immuron Ltd. Highlights Market Opportunity Following Recent Studies on Antibiotic Correlation to C. Difficile Infections

MELBOURNE, Australia, Oct. 17, 2017 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC) (NASDAQ:IMRN), an Australian microbiome biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the treatment of gut-mediated diseases, today highlighted recent results from multiple independent studies that address the challenge of utilizing antibiotics … [Read more...]